Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Half Year ended 30th September, 2026
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Date of Board Meeting / Approval: 5th November, 2026 (4:00 p.m. to 4:30 p.m.)
Audit Opinion: Unqualified with Emphasis of Matter
Auditor's Comment: Emphasis on disputed electricity duty liability with aggregate provision of ₹2,052.13 lakhs and ₹35 crore deposit with Supreme Court
Key Financial Highlights [Rs in Lakhs]
Standalone Results:
Quarter Ended 30.09.2026:
- Revenue from Operations: ₹2,769 (vs ₹5,404 in Q2 FY26, -48.8% YoY)
- Total Income: ₹9,931 (vs ₹11,884 in Q2 FY26, -16.4% YoY)
- Net Profit: ₹6,702 (vs ₹7,563 in Q2 FY26, -11.4% YoY)
- EPS: ₹2.61 (vs ₹2.95 in Q2 FY26)
Half Year Ended 30.09.2026:
- Revenue from Operations: ₹7,395 (vs ₹10,192 in H1 FY26, -27.4% YoY)
- Total Income: ₹15,112 (vs ₹17,018 in H1 FY26, -11.2% YoY)
- Net Profit: ₹8,169 (vs ₹9,275 in H1 FY26, -11.9% YoY)
- EPS: ₹3.18 (vs ₹3.61 in H1 FY26)
Other Equity: ₹92,272 (as at 30.09.2026)
Cash and Cash Equivalents: ₹117 lakhs
Debt: Not specified
Consolidated Results:
Quarter Ended 30.09.2026:
- Revenue from Operations: ₹3,025 (vs ₹5,586 in Q2 FY26, -45.8% YoY)
- Total Income: ₹10,180 (vs ₹12,078 in Q2 FY26, -15.7% YoY)
- Net Profit after tax: ₹6,757 (vs ₹7,606 in Q2 FY26, -11.2% YoY)
- Share of Associate's Profit: ₹9,530
- Net Profit after tax and Share of Associate's Profit: ₹16,287
- EPS: ₹6.34 (vs ₹5.00 in Q2 FY26)
Half Year Ended 30.09.2026:
- Revenue from Operations: ₹7,899 (vs ₹10,561 in H1 FY26, -25.2% YoY)
- Total Income: ₹15,650 (vs ₹17,412 in H1 FY26, -10.1% YoY)
- Net Profit after tax: ₹8,326 (vs ₹9,386 in H1 FY26, -11.3% YoY)
- Share of Associate's Profit: ₹14,449
- Net Profit after tax and Share of Associate's Profit: ₹22,774
- EPS: ₹8.87 (vs ₹7.40 in H1 FY26)
Other Equity: ₹2,62,430 (as at 30.09.2026)
Cash and Cash Equivalents: ₹175 lakhs
Debt: Not specified
Segment-wise Performance [Rs in Lakhs]:
Consolidated Segment Revenue Q2 FY27:
- Active Pharmaceutical Ingredients Business: ₹679 (vs ₹1,030 in Q2 FY26, -34.1% YoY)
- Real Estate Business: ₹2,345 (vs ₹4,556 in Q2 FY26, -48.5% YoY)
- Total Revenue from Operations: ₹3,025
Consolidated Segment Results (Profit before Taxes and Interest) Q2 FY27:
- Active Pharmaceutical Ingredients Business: ₹(17) loss (vs ₹195 profit in Q2 FY26)
- Real Estate Business: ₹467 profit (vs ₹2,041 profit in Q2 FY26, -77.1% YoY)
- Total Segment Results: ₹450 profit
Standalone Segment Revenue Q2 FY27:
- Active Pharmaceutical Ingredients Business: ₹679 (vs ₹1,030 in Q2 FY26, -34.1% YoY)
- Real Estate Business: ₹2,089 (vs ₹4,373 in Q2 FY26, -52.2% YoY)
- Total Revenue from Operations: ₹2,769
Standalone Segment Results (Profit before Taxes and Interest) Q2 FY27:
- Active Pharmaceutical Ingredients Business: ₹(17) loss (vs ₹195 profit in Q2 FY26)
- Real Estate Business: ₹376 profit (vs ₹1,966 profit in Q2 FY26, -80.9% YoY)
- Total Segment Results: ₹359 profit
Corporate Actions:
Not Specified
Other Significant Information:
- Entities included in consolidation: Alembic City Limited (Subsidiary), Alembic Pharmaceuticals Limited (Associate)
- Subsidiary financials reviewed by other auditors
- Previous periods' figures regrouped/rearranged for comparability